Silexion TherapeuticsSLXN
13F holders, Q2 2025 (June 30)6holders +1
2new positions
1sold out
$0.81avg. 13F price*
At the end of Q2 2025, 6 institutions reported holding Silexion Therapeutics Corp. (SLXN) in their 13F filings, up 1 from Q1 2025. 2 opened new positions and 1 sold out. The largest holders were Wildcat Capital Management, LLC ($92K), UBS Group AG ($88K) and Meyer Handelman Co. ($27K).
- Company
- Silexion Therapeutics Corp.
- CUSIP
- G1281K122
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $21K |
| Exits | 1 | $18K |
All 13F filers, Q1 2025 → Q2 2025: 61,888 shares bought and 16,411 shares sold, net +45,477 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Wildcat Capital Management, LLC | 0.05% | No change | 113,428 | $92K |
| UBS Group AG | 0.00% | Add +49.9% | 109,257 | $88K |
| Meyer Handelman Co. | 0.00% | No change | 32,967 | $27K |
| Virtu Financial LLC | 0.00% | New | 14,264 | $12K |
| StoneX Group Inc. | 0.00% | New | 11,241 | $9K |
| Bank of America Corp. | 0.00% | No change | 500 | $405 |
"% of holder's portfolio" is SLXN's weight in each manager's 13F, not the share of Silexion Therapeutics Corp. the manager owns.